Your browser doesn't support javascript.
loading
Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients
Sallum, Adriana Maluf Elias; Kiss, Maria Helena Bittencurt; Sachetti, Silvana; Resende, Maria Bernadate Dutra; Moutinho, Kelly Cristina; Carvalho, Mary de Souza; Silva, Clovis Arthur Almeida; Marie, Suely Kazue Nagahashi.
  • Sallum, Adriana Maluf Elias; University of São Paulo. Medical School. Pediatric Department. São Paulo. BR
  • Kiss, Maria Helena Bittencurt; University of São Paulo. Medical School. Children's Institute. São Paulo. BR
  • Sachetti, Silvana; São Paulo Medical School. Santa Casa de Misericórdia. Pediatric Rheumatology Unit. BR
  • Resende, Maria Bernadate Dutra; University of São Paulo. Medical School. Department of Neurology. São Paulo. BR
  • Moutinho, Kelly Cristina; s.af
  • Carvalho, Mary de Souza; University of São Paulo. Medical School. Clinical Hospital. Neurology Department. São Paulo. BR
  • Silva, Clovis Arthur Almeida; University of São Paulo. Medical School. Children's Institute. Pediatric Rheumatology Unit. São Paulo. BR
  • Marie, Suely Kazue Nagahashi; University of São Paulo. Medical School. Department of Neurology. Laboratory of Neuromuscular Diseases. São Paulo. BR
Arq. neuropsiquiatr ; 60(4): 889-899, Dec. 2002. ilus, tab, graf
Article in English | LILACS | ID: lil-326156
RESUMO
This study was based on a prospective and a retrospective analysis of 35 patients who met Bohan and Peter criteria for juvenile dermatomyositis diagnosis.The mean follow-up time was three years ten months. Calcinosis was present in five (14.28 percent) patients, cutaneous ulcers in four (11.42 percent), and systemic involvement in nine (27.71 percent) patients. All patients presented alterations in the serum levels of muscle enzymes, and all of them were submitted to muscle biopsy as a diagnostic procedure. Nine (25.71 percent) patients received corticotherapy prior to and 26 (74.28 percent) after the muscle biopsy. Chloroquine, methotrexate, cyclosporine, cyclophosphamide and intravenous immunoglobulin were used in patients with poor response to corticotherapy. Continuation of cutaneous manifestations was observed in 4 (11.43 percent) patients, laboratorial activity in 1 (2.85 percent), cutaneous and laboratorial activities in 3 (8.57 percent). Ten (28.57 percent) patients were out of activity, and 17 (48.57 percent) in remission at study end-point, on March 2002. Two (5.71 percent) patients died
Subject(s)
Full text: Available Index: LILACS (Americas) Main subject: Dermatomyositis Type of study: Observational study / Prognostic study Limits: Child / Child, preschool / Female / Humans / Infant / Male Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2002 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: São Paulo Medical School/BR / University of São Paulo/BR

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Dermatomyositis Type of study: Observational study / Prognostic study Limits: Child / Child, preschool / Female / Humans / Infant / Male Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2002 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: São Paulo Medical School/BR / University of São Paulo/BR